Aving No Risk Of Amyloid Related Imaging Abnormalities Topline Results For The Phase 3 Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana

- Tau aggregation inhibitor, HMTM, is an oral drug with a strong safety profile, having no risk of amyloid related imaging abnormalities - Topline results for the Phase 3 study, LUCIDITY, were shared at the Clinical Trials in Alzheimer's Disease (CTAD) conference on Wednesday, 30th November 2022, in San Francisco - For people with early Alzheimer's (MCI), HMTM improvement in cognition over pre-treatment baseline now shown to be sustained over 18 months ABERDEEN, Scotland and SINGAPORE, Dec. 1, 2022 /PRNewswire/ TauRx Pharmaceuticals Ltd is a global leader in Tau-based research in Alzheimer's disease (AD), being the only company running late-stage clinical trials for a potential therapy designed to target the Tau pathology of Alzheimer's. Pathological aggregation of Tau correlates with clinical disease severity and brain atrophy. As a hallmark of the disease, it is recognised as a key target for disease modifying treatments. This approach by TauRx contrasts to many in t ....

United Kingdom , San Francisco , United States , George Grossberg , St Louis University School Of Medicine , University Of Aberdeen , Taurx Pharmaceuticals Ltd , Clinical Trials , Director Division , Geriatric Psychiatry Department , Behavioural Neuroscience , Au Aggregation Inhibitor , S An Oral Drug Witha Strong Safety Profile , Aving No Risk Of Amyloid Related Imaging Abnormalities Topline Results For The Phase 3 Study , Ere Shared At The Clinical Trials In Alzheimer 39s Disease Ctad Conference On Wednesday , 0th November 2022 , N San Francisco For People With Early Alzheimer 39s Mci , Mtm Improvement In Cognition Over Pre Treatment Baseline Now Shown To Be Sustained 18 Months Aberdeen , Scotland And Singapore , Dec 1 , 022 Prnewswire Taurx Pharmaceuticals Ltd Isa Global Leader In Tau Based Research Alzheimer 39s Disease Ad , Eing The Only Company Running Late Stage Clinical Trials Fora Potential Therapy Designed To Target Tau Pathology Of Alzheimer 39s Pathological Aggregation Correlates With Disease Severity And Brain Atrophy Asa Hallmark , T Is Recognised Asa Key Target For Disease Modifying Treatments This Approach By Taurx Contrasts To Many In The Field , Here The Focus Has Largely Been On Role Of Beta Amyloid Experts In Field Are Increasingly Looking At Alternative Therapeutic Approaches To Finda Breakthrough Treatment That Offers Clinically Meaningful Benefit , Ase Of Administration And Low Burden Care Associated Witha Reassuring Safety Profile Supportinga Path To Regulatory Submissions , He Most Recent Data From Lucidity Shows Sustained Improvement In Cognition Over 18 Months Pre Treatment Levels Those Participants With Mci Due To Ad ,